Details of the Drug Reposition

General Information of This Drug (ID: DMNH3PG)

Drug Name
Etoposide   DMNH3PG
Synonyms
etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; Etoposido; Vepesid J; Eposin; Etoposidum [INN-Latin]; Etoposide (VP16); VP 16-213; VP 16 (pharmaceutical); Etoposido [INN-Spanish]; Etopophos (phosphate salt); VP-16-213; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; VP 16213; UNII-6PLQ3CP4P3; NK 171; NSC 141540; CCRIS 2392; HSDB 6517; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EINECS 251-509-1; NSC-141540; Eposide; Etopol; Etosid; Vepeside; Demethyl EpipodophyllotoxinEthylidine Glucoside; E0675; Demethyl-epiodophyllotoxin ethylidene glucoside; Epipodophyllotoxin VP-16213; Eposin (TN); Etopophos (TN); Trans-Etoposide; VePESID (TN); Vepesid (TN); DEMETHY-EPIPODOPHYLLOTOXIN, ETHYLIDENE GLUCOSIDE; VP-16 (TN); Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; Etoposide (JP15/USP/INN); Etoposide [USAN:INN:BAN:JAN]; Eposin, Vepesid, VP-16, Toposar, Etoposide; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI); Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
10 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Kidney neoplasm DISBNZTN N.A. Approved [1]
Hamartoma DIS0I87H N.A. Approved [1]
Childhood kidney Wilms tumor DIS0NMK3 N.A. Approved [1]
Beckwith-Wiedemann syndrome DISH15GR N.A. Approved [1]
Adult kidney Wilms tumor DIS79FJF N.A. Approved [1]
Adult acute monocytic leukemia DISG6BLX N.A. Approved [1]
Acute myelogenous leukaemia DISCSPTN 2A41 Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Small-cell lung cancer DISK3LZD 2C25.Y Approved [1]
Testicular cancer DIS6HNYO 2C80 Approved [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [3]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 1 [4]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
------------------------------------------------------------------------------------

References

1 Etoposide FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 075635.
3 ClinicalTrials.gov (NCT04356690) Etoposide in Patients With COVID-19 Infection. U.S. National Institutes of Health.
4 Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia